Ziccum AB (publ) (ZICC.ST)
SEK 0.25
(0.0%)
SEK 0.25
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.56 Million SEK | 16.66% |
| 2022 | -28.95 Million SEK | -37.12% |
| 2021 | -21.11 Million SEK | -22.52% |
| 2020 | -17.23 Million SEK | -97.63% |
| 2019 | -8.72 Million SEK | -107.15% |
| 2018 | -4.21 Million SEK | -834.17% |
| 2017 | -450.66 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -5.92 Million SEK | 25.26% |
| 2024 Q1 | -4.02 Million SEK | 51.65% |
| 2024 Q2 | -7.92 Million SEK | -97.07% |
| 2023 FY | -24.13 Million SEK | 16.66% |
| 2023 Q3 | -3.89 Million SEK | 22.94% |
| 2023 Q2 | -5.06 Million SEK | -2.51% |
| 2023 Q1 | -4.93 Million SEK | 38.81% |
| 2023 Q4 | -8.31 Million SEK | -113.34% |
| 2022 Q1 | -6.34 Million SEK | 2.05% |
| 2022 FY | -28.95 Million SEK | -37.12% |
| 2022 Q4 | -8.06 Million SEK | -20.87% |
| 2022 Q3 | -6.67 Million SEK | 15.23% |
| 2022 Q2 | -7.87 Million SEK | -24.18% |
| 2021 Q4 | -6.47 Million SEK | -28.31% |
| 2021 Q3 | -5.04 Million SEK | 3.2% |
| 2021 Q2 | -5.21 Million SEK | -18.81% |
| 2021 Q1 | -4.38 Million SEK | -35.86% |
| 2021 FY | -21.11 Million SEK | -22.52% |
| 2020 FY | -17.23 Million SEK | -97.63% |
| 2020 Q3 | -5.31 Million SEK | -12.91% |
| 2020 Q4 | -3.22 Million SEK | 39.27% |
| 2020 Q2 | -4.7 Million SEK | -18.32% |
| 2020 Q1 | -3.98 Million SEK | -19.05% |
| 2019 Q4 | -3.34 Million SEK | -142.25% |
| 2019 Q3 | -1.38 Million SEK | 39.9% |
| 2019 Q2 | -2.29 Million SEK | -35.94% |
| 2019 Q1 | -1.68 Million SEK | 4.47% |
| 2019 FY | -8.72 Million SEK | -107.15% |
| 2018 Q1 | -137 Thousand SEK | -11.38% |
| 2018 Q2 | -573 Thousand SEK | -318.25% |
| 2018 FY | -4.21 Million SEK | -834.17% |
| 2018 Q4 | -1.76 Million SEK | -3.15% |
| 2018 Q3 | -1.71 Million SEK | -199.13% |
| 2017 Q2 | -112 Thousand SEK | 0.0% |
| 2017 FY | -450.66 Thousand SEK | 0.0% |
| 2017 Q4 | -123 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.52 Million SEK | -30.493% |
| Amniotics AB (publ) | -29.07 Million SEK | 25.842% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -47.268% |
| BioArctic AB (publ) | 252.64 Million SEK | 108.534% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 94.391% |
| Saniona AB (publ) | -81.06 Million SEK | 73.404% |
| Simris Alg AB (publ) | -36.63 Million SEK | 41.149% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 93.294% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -7.056% |
| NextCell Pharma AB | -43.17 Million SEK | 50.06% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -26.109% |
| AcouSort AB (publ) | -17.48 Million SEK | -23.292% |
| Active Biotech AB (publ) | -46.48 Million SEK | 53.618% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 91.341% |
| Camurus AB (publ) | 532.35 Million SEK | 104.05% |
| Cantargia AB (publ) | -290.01 Million SEK | 92.566% |
| Genovis AB (publ.) | 54.22 Million SEK | 139.761% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 81.264% |
| Mendus AB (publ) | -100.65 Million SEK | 78.579% |
| Kancera AB (publ) | -65.04 Million SEK | 66.852% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -515.121% |
| LIDDS AB (publ) | -40.67 Million SEK | 46.993% |
| Lipum AB (publ) | -37.25 Million SEK | 42.127% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -74.279% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 219.718% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -31.455% |
| OncoZenge AB (publ) | -15.9 Million SEK | -35.58% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 93.055% |
| Xintela AB (publ) | -57.23 Million SEK | 62.333% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 48.276% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 88.073% |
| CombiGene AB (publ) | -36.3 Million SEK | 40.615% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 85.29% |
| Intervacc AB (publ) | -93.57 Million SEK | 76.961% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -2451.479% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -38.989% |
| Corline Biomedical AB | -1.78 Million SEK | -1105.817% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 88.073% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 61.095% |
| Aptahem AB (publ) | -10.1 Million SEK | -113.365% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 83.984% |
| Fluicell AB (publ) | -26.87 Million SEK | 19.789% |
| Biovica International AB (publ) | -126.07 Million SEK | 82.899% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 49.277% |
| Abliva AB (publ) | -96.54 Million SEK | 77.669% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 93.362% |
| 2cureX AB (publ) | -36.36 Million SEK | 40.709% |
| I-Tech AB | 24.43 Million SEK | 188.234% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.266% |
| Cyxone AB (publ) | -21.66 Million SEK | 0.466% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 79.654% |
| Biosergen AB | -27.26 Million SEK | 20.924% |
| Nanologica AB (publ) | -69.96 Million SEK | 69.184% |
| SynAct Pharma AB | -224.49 Million SEK | 90.396% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 51.195% |
| BioInvent International AB (publ) | -369.94 Million SEK | 94.172% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 9.995% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 91.493% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -237.231% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 80.562% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -86.408% |